Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)
NCT03180450 · Sclnow Biotechnology Co., Ltd. · PHASE1/PHASE2 · suspended · last registry update 2025-05-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Others” | – | Registry record, Sclnow Biotechnology Co., Ltd. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-13Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03808610)
- 2026-05-13Also stopped (withdrawn): University of Southampton, a drug against NR3C1 (NCT06566157)
- 2026-05-06Results posted on the registry: University of Washington, Dronabinol (NCT04374773)
- 2026-05-05Also stopped (withdrawn): Children's Oncology Group, Cytarabine + Methotrexate (NCT07498465)
- 2026-04-13Results posted on the registry: Massachusetts General Hospital, a drug against NR3C1 (NCT05702723)
- 2026-04-02Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT03220022)
- 2026-03-25Also stopped (terminated): Claire Bourgeois, Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy (NCT05845125)
- 2026-03-24Also stopped (withdrawn): Tarsus University, a drug against NR3C1 (NCT07462390)
- 2026-03-16Also stopped (terminated): M.D. Anderson Cancer Center, Abiraterone Acetate + Apalutamide (NCT03360721)
- 2026-03-04Phase 3 first posted: Biobizkaia Health Research Institute, Platelet-rich Plasma Local injection + betamethasone and Ropivacaine (NCT07448285)
- 2026-02-27Results posted on the registry: Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2026-01-22Phase 3 first posted: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., MC2-01 cream + MC2-01 vehicle (NCT07357831)
- 2026-01-12Phase 3 first posted: University of Virginia, Hydrocortisone administration + Expanded antimicrobial therapy (NCT07332325)
- 2025-10-23Phase 3 first posted: SWOG Cancer Research Network, Cyclophosphamide + Doxorubicin Hydrochloride (NCT07220187)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
- 2025-07-18Phase 3 first posted: Children's Oncology Group, Bortezomib + Calaspargase Pegol (NCT07072585)
- 2025-06-25Phase 3 first posted: Centre Hospitalier Universitaire, Amiens, hydrocortisone plus fludrocortisone + placebo of hydrocortisone plus fludrocortisone (NCT07037043)
- 2025-04-08Phase 3 first posted: Laboratorios Silanes S.A. de C.V., Desloratadine / Betamethasone in fixed dose + Desloratadine (NCT06916884)
- 2025-02-24Results posted on the registry: Neurocrine UK Limited, Chronocort + Cortef (NCT05063994)
- 2024-10-24Results posted on the registry: Neurocrine UK Limited, Hydrocortisone (NCT03062280)
- 2024-09-24Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT02003222)
- 2024-07-11Phase 3 first posted: Fayoum University, Methylprednisolone + Dexamethasone (NCT06496997)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision